you're actually somewhat right for a change. anatabine was quite a find. it helps with so many disorders, they're seeking the most beneficial avenues to pursue. why settle for one niche when it aids in so many? ironically, you're headline seems to refer to yourself...'trying to find a purpose.' we all are, or at least should be, and you are apparently floundering. ask yourself what YOUR purpose is in life. you don't know? is this the pinnacle of your reason for being? bashing and belittling companies in order to gain by greed? let's be honest...you've burned through 47 years thus far. and to what avail? what do you have to show for your time? your posts speak louder than the answer you conjur up within. don't kid yourself. until you can clearly define your own purpose, a meaningful, lasting purpose that transcends your short span here and is other than about you, what authority have you in ridiculing the purpose of anyone or anything else?
there was surely an exclusive rights to sell deal made with gnc for some time...my guess, 2-4 years...anyone privy to typical exclusive rights terms with gnc? by that time, a time release version will be well out, more recognition received, and additional studies will be complete, with an actual drug ready or soon to be available. it will be prime time to branch out to cvs, walgreens, sam's, costco, etc. gnc has the upper hand at the moment with marketing and selling, if you will...and that's fine, for we need them. it's a win-win. but 'shortly', rcp will gain leverage just as the exclusivity runs its course and opens to others.
definitely. jonnie will remain to help manage the company. he undoubtedly wants mullan as well...it's in his best interest to further his company and boost share price. hiring mullan is like hiring the best 'ambassador' thus far...a leader in Alzheimer's research. he will be respected and listened to in places fred and isner would never get the time of day...though both admired in their own domains.
it will be virtually unanimous, no question...except for that one guy way in the back...there's always that one guy. it's what everyone wants...shareholders, new directors, new ceo and pres, even jw and pp.
mullan's plan? facial crème...facial serum? lowest priority. anatabloc? of course, especially in short-term, but mid-priority, imo.
he obviously wants the heavy hitting goods...a line of fda approved drugs treating a range of disorders. an incredible team with mullan, chapman, wright, and other new directors coming aboard. mullan will get the attention and respect he's due, chapman has contacts and experience in pharmaceutical channels, and curtis will 'fast-track' as quickly as possible.
Curtis. Will get it. Through.
Curtis Wright, M.D., MPH, 63, has served as Senior Vice-President, Medical/Clinical Director of our pharmaceutical subsidiary, Rock Creek Pharmaceuticals, Inc. since February 2008. Dr. Wright previously served as Vice President of Clinical and Regulatory Affairs for Adolor Corporation from 1997 to 1998, and Executive Director, Medical Affairs and subsequently Executive Director of Risk Assessment for Purdue Pharma from 1998 to 2004. Immediately prior to joining Rock Creek Pharmaceuticals, Inc., Dr. Wright served as Executive Vice President for Risk Management and Regulatory Affairs at Javelin Pharmaceuticals, Inc., Cambridge, Massachusetts from 2004 to 2008. Dr. Wrights career at the FDA, from 1989 through October 1997, included multiple senior scientific positions in the Center for Drug Evaluation and Research, including Deputy Director, and subsequently, Acting Director of his division. Dr. Wright received his medical degree, with distinction, from George Washington University and received a masters degree in Public Health from the John Hopkins University.
just a few takes from the filing...
"Mr. Williams will continue as a non-executive employee of the Company for one year...Mr. Williams has further indicated that, following the one-year period described above, he is willing to serve as a consultant to the Company to provide continued assistance with patent prosecutions and new product development. The terms of any such arrangement would be determined by Mr. Williams and the New Board."
GOOD, jonnie stays!
"Mr. Williams is expected to perform such duties as may be prescribed by Dr. Mullan or Dr. Chapman, which may include efforts in connection with product development and the continued expansion of the Company’s patent portfolio."
"Our Existing Board believes that the Company will benefit from the reputations of Drs. Mullan and Chapman, particularly as related to potential business partners and collaborations. Drs. Mullan and Chapman are well recognized in the pharmaceutical industry, and our Board of Directors believes we will benefit from their respective industry contacts."
"we believe that the government and internal investigations that the Company has been subject to are nearing completion. See our Quarterly Report on Form 10-Q for the period ended September 30, 2013, filed November 12, 2013. Our Existing Board considered that, given the status of such investigations, it was appropriate to consider the corporate transition matters at this time."
third quarter REVENUES decreased by 10%, partly due to the increased 300 count bottles and partly due to gnc assuming a greater stake in the selling and profit-taking, while 'general and administrative SELLING' decreased by 44% in the same quarter. that's a sizeable decrease in selling expense as gnc bears a larger marketing presence in our stead.
it cannot be a LEVEL playing field, pablo. society would have to be rational, just, and discerning, holding integrity at a premium. what a deranged and unrecognizable world THAT would be. : \
from 99.5 Blakefm country radio:
'Thomas Rhett is Selling Out Shows'
"Well – it’s almost time! The 4th Annual Anatabloc Taste of Country Christmas Tour driven by Ford is this Saturday, Nov. 16th! Thomas Rhett will take the Suddenlink Stage at Wild West! Here’s some things you need to know…Thomas Rhett kicked this tour off last weekend in Abilene, TX, Wichita Falls, TX and Lawton, OK – and each show SOLD OUT! Of course this tour is predicted to sell out with Thomas Rhett’s latest single “It Goes Like This” being #2 on Billboard’s Hot Country Song and his album he released Oct 29th, It Goes Like This, is also #2 on Billboard’s Top Country Album. Not to mention Thomas Rhett has recently made appearances on NBC’s The Tonight Show with Jay Leno, the nationally syndicated Queen Latifah Show and tonight (Nov 13) he will be on NBC’s Late Night with Jimmy Fallon (make sure you set your DVR’s)."
Context: Hashimoto’s thyroiditis is less prevalent in tobacco smokers. Anatabine, an alkaloid found in Solanaceae plants including tobacco, has been reported to ameliorate a mouse model of Hashimoto’s thyroiditis.
Objective: The effects of anatabine in patients with Hashimoto’s thyroiditis.
Design, Setting, Patients, and Intervention: Double-blind, randomized, placebo-controlled multi-site study. A total of 146 patients (70 treated with anatabine, and 76 placebo) completed the study. Approximately 50% of patients in each group were on levothyroxine medication. Anatabine lozenges (9–24 mg/day) or placebo, each containing vitamins A and D3, were administered orally 3 times a day for three months.
Main Outcome Measures: Assessment of serum thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TgAb). Safety was assessed though adverse events (AEs), clinical laboratory evaluations, and vital sign measurements.
Results: Anatabine treated patients had a significant reduction in absolute serum TgAb levels from baseline by study end relative to those on placebo (p=0.027); however, there were no significant changes or differences in treatment group means for TPOAb or TgAb. Mean (±SD) TgAb values decreased by 46.2 (±101.1) and 3.9 (±83.9) WHO units for the anatabine and placebo groups, respectively. Significantly more patients had a 20% drop in TgAb in the anatabine than placebo group (p=0.023). Overall the anatabine supplement was safe and well tolerated, although significantly (p
"Early Release articles are PDF versions of manuscripts that have been peer reviewed and accepted but not yet copyedited. The manuscripts are published online as soon as possible after acceptance, on a weekly basis, before the copyedited, typeset articles are published. They are posted "as is" (i.e., as submitted by the authors at the modification stage), and do not reflect editorial changes. No corrections/changes to the PDF manuscripts are accepted. Accordingly, there likely will be differences between the Early Release manuscripts and the final, typeset articles. The manuscripts remain listed on the Early Release page until the final, typeset articles are posted. At that point, the manuscripts are removed from the Early Release page."
if interested, first go to: jcem.endojournals.org
once there, add to the END of above address: /content/suppl/2013/10/31/jc.2013-2951.DC1/JC-13-2951_4tabs_2Figs.pdf
However, when assessed at the chronic timepoint of 6 months after injury/sham, anatabine treated r-mTBI mice showed a significantly lower latency to the target hole than untreated r-mTBI mice during the probe trial and did not show any significant differences from sham controls. Additionally, anatabine treated r-mTBI mice showed a significantly lower path length than untreated r-mTBI during the first day of acquisition testing at the 6 month timepoint.
Daily treatment with the anti-inflammatory dietary supplement anatabine significantly improved long-term spatial memory after r-mTBI at a 6 month timepoint. Although anatabine treated mice still showed significant spatial learning deficits 6 months after TBI, spatial memory was significantly improved compared to untreated controls. Pathological analyses of the mice is ongoing. Future studies will explore the underlying mechanism of this effect, which, from our previous work on anatabine’s anti-inflammatory effects, we expect to involve inhibition of the chronic neuroinflammation seen in this model of repetitive head injury. Anatabine shows promise as a dietary supplement for improving the long-term outcome after repetitive mild head injury.
Disclosures: S. Ferguson: None. B. Mouzon: None. L. Abdullah: None. G. Crynen: None. M. Mullan: None. V. Mathura: None. M. Mullan: None. F. Crawford: None.
Keyword(s): TRAUMATIC BRAIN INJURY
Support: Department of Defense award (W81XWH-07-01-0759) to Dr. Crawford
The Roskamp Foundation
Department of Veterans Affairs
Presentation Title: Treatment with anatabine significantly improves chronic outcome in a mouse model of repetitive mild TBI
PRESENTATION TIME: Sunday, Nov 10, 2013, 1:30 PM - 1:45 PM
Topic: ++C.11.c. Brain: Therapeutic strategies
Authors: *S. FERGUSON, B. MOUZON, L. ABDULLAH, G. CRYNEN, M. MULLAN, V. MATHURA, M. MULLAN, F. CRAWFORD;
Roskamp Inst., Sarasota, FL
Abstract: We have previously demonstrated that repetitive mild TBI (r-mTBI) results in chronic and progressive neuroinflammation and spatial memory impairment in a mouse model. We have now shown that treatment with an anti-inflammatory dietary supplement, anatabine, significantly improved spatial memory 6 months after r-mTBI.
Male C57BL/6J mice 10 weeks old received either an r-mTBI (a closed head injury with 5 impacts on the midline, at a 1mm depth at 5 m/second with an inter-injury interval of 48 hours) or repeated anesthesia (r-sham; 5 anesthesias with an interval of 48 hours) and were treated with either anatabine (2mg/kg IP) or placebo (PBS) 30 minutes after surgery. Anatabine treated mice continued to receive anatabine orally, in their water, at an estimated dose of 20mg/kg per day for the duration of the experiment. Neurobehavioral testing consisted of Rotarod at 1, 3, 5, and 7 days after the final TBI or anesthesia alone (5-50 rpm over 5 minutes) followed by Barnes maze acquisition testing on days 8-13 with a probe trial on day 14. Rotarod and Barnes maze testing were repeated 6 months later.
R-mTBI induced a significant impairment in acute motor function and spatial memory compared to sham mice as #$%$essed by Rotarod and Barnes maze testing. At the acute timepoint after injury, treatment with anatabine did not alleviate impairments in motor function or spatial learning. However, when #$%$
i may be wrong, but i'm not convinced that jonnie is leaving the company as the media more than alludes toward. he's leaving his position, i realize, and i know he's remaining for a year in another capacity, but who's to say he won't be contracted for the following year, and year after? if he were a 'bad' employee, he'd be booted out...and yet, he's not. do i feel he should step down from his ceo position? of course...it's a completely different business model now...not to mention his name's a bit tainted presently. do i want him gone from the company? definitely not. this company is his baby, he's the founder, a major investor of time, money, and creative genius, if you will. hard to believe he worked this long with star and is exiting right when potential is greatest. a much more 'silent' position he will retain, away from the media's attention, but a position no less...and that's a good thing...imo.
forgive me as this is so painfully obvious, and yet, some may overlook the significance in mullan's move. he is not simply changing from ceo of one company to ceo of another. as star realizes a paradigm shift into rcp, so michael is transitioning himself. for years, decades, he has been researching alzheimer's and other disorders, seeking to find a cure or remedy. and while research most assuredly continues, mullan now begins to morph into a ceo who leads a company into PROVIDING a remedy, not merely in pursuit of one. a researcher for years and years, mullan now shifts his occupation to FULFILL his entire lifelong mission and career pursuit. that's huge, imo.
3) "Beginning in the three months ended June 30, 2013, our company has sought to further align our marketing and distribution efforts with GNC as our primary strategic partner for growth. We believe that this strategic shift should result in lower customer acquisition cost and overall increased net sales due to higher sales volume. In the three months ended September 30, 2013 we experienced a decline in sales volumes in our company’s internet sales and although sales volumes at GNC increased, our overall sales volume and revenue for the three months ended September 30, 2013 declined given the lower wholesale pricing to GNC as compared to our retail pricing for product sold through the Company’s website."
Presentation time: Wednesday, Nov 13, 2013, 10:00 AM -11:00 AM
Presentation Title: Behavioral effects of anatabine in wild-type and transgenic mouse models of Alzheimer’s disease
Authors: *M. VERMA, D. BEAULIEU-ABDELAHAD, F. CRAWFORD, M. MULLAN, D. PARIS;
Roskamp Inst., Sarasota, FL
Abstract: In this study, we have investigated the impact of anatabine, a minor alkaloid present in plant of the Solanacea family on the behavior of a transgenic mouse model of Alzheimer’s disease (AD) and wild-type mice using a battery of behavior tests. In particular, we show that the acute administration of anatabine dose dependently reduces anxiety in wild-type mice. Similarly, a reduction of anxiety was observed following a chronic treatment in wild-type mice. Interestingly, a chronic anatabine treatment initiated in a transgenic mouse model of AD (Tg PS1/APPsw) presenting already pathological Aβ deposition and cognitive impairment (active treatment) appears to reduce hyperactivity, disinhibition and to improve social interaction and social memory deficits which affects Tg PS1/APPsw mice. Overall our data show that anatabine improves cognition in Tg PS1/APPsw mice and elicits anxiolytic properties in wild-type mice. Further studies are underway to investigate the impact of anatabine on AD like pathology in Tg PS1/APPsw mice.